Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Cue Biopharma, Inc. (CUE) is a Biotechnology company based in US with a market capitalization of $57.5M. Revenue grew 195.8% year-over-year and free cash flow was negative at -$21.9M. This page tracks CUE's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 41 employees · IPO Jan 2, 2018
Valuation
Valuation & price
$23.01as of May 17, 2026· -35.6% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
2.17
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$57.5M
Market cap
195.8%
Revenue growth (YoY)
100.0%
Gross margin
-$21.9M
Free cash flow (USD)
-$22.9M
Net debt
Net cash position
68.2%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: May 14, 2026 (EPS $-1.08)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- FinancingJun 18, 2026Filing
Securities Registration
- FinancingJun 3, 2026Filing
Securities Registration
- 8-K eventJun 3, 2026Filing
Stockholder Meeting Results
- 8-K eventJun 2, 2026Filing
Board Restructuring
- Quarterly reportMay 14, 2026Filing
10-Q Filed
- 8-K eventMay 14, 2026Filing
Earnings Release
- 8-K eventMay 1, 2026Filing
Securities Purchase Agreement
- 8-K eventApr 22, 2026Filing
Reverse Stock Split
- 8-K eventApr 13, 2026Filing
Annual Meeting Results
- 8-K eventApr 7, 2026Filing
Collaboration Milestone Achieved
Questions
Frequently asked questions
What is Cue Biopharma, Inc.'s market cap?
Cue Biopharma, Inc. (CUE) has a market capitalization of $57.5M.
What is CUE's P/E ratio?
A meaningful P/E ratio is not available for CUE — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is CUE's price-to-book (P/B) ratio?
CUE trades at 2.17 times book value per share.
When did Cue Biopharma, Inc. last report earnings?
CUE last reported earnings on May 14, 2026; the next date is not yet scheduled.
Are insiders buying CUE stock?
SEC Form 4 filings show no open-market insider buys at Cue Biopharma, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.